9th IAS Conference on HIV Science*
  • 1
  • 2
  • 3

Latest Content

10 of 15 Shown
10 of 15 Shown
Show 5 More

Conference News – Reported by NAM

US HIV funding decisions on PEPFAR in 2017 will have critical effect on ability to reach 90-90-90 goals
First protease inhibitor combination pill maintains viral suppression
Adolescents with HIV do better in more prosperous African countries, even with treatment
France’s next PrEP study aims to assess the wider impact of PrEP on the HIV epidemic
Dutch study finds out whether gay men prefer daily or on-demand PrEP
Long-acting cabotegravir injection shows promise for HIV prevention
Doravirine combination pill looks good for initial HIV treatment
Acute kidney injury ‘uncommon’ but unpredictable on tenofovir and ritonavir
Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows
Medical male circumcision for HIV has benefits for women too
Demonstration projects explore the feasibility of PrEP for adolescents and young women in South Africa
Ipergay trial: PrEP still protected people who had less sex and used it less often
Another HIV vaccine efficacy trial will start this year
Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection
90-90-90 progress in southern Africa: HIV testing gap needs to be closed in young people and men
Can self-testing engage 'hard-to-reach' men with HIV testing?
Integrase inhibitors not causing higher rates of adverse birth outcomes, Botswana and French studies show
New guidance says start HIV treatment within 7 days of diagnosis - but is everyone ready?
International study of gay couples reports no transmissions from an HIV-positive partner on treatment
New integrase inhibitor bictegravir works well for first-line HIV treatment
Hepatitis C treatment is effective and feasible in Africa
High uptake of HIV self testing by female sex workers in African countries
South African child has controlled HIV off treatment for 8.5 years
Programme to provide free self tests helps gay men to test for HIV more often
Less frequent clinic visits for HIV care: fine tuning needed
Improved treatment for cryptococcal meningitis in HIV could save thousands of lives – if generic drug becomes available
Swaziland: new infections halved in five years as HIV treatment scales up
Long-acting cabotegravir + rilpivirine injection shows good results at 96 weeks
London gonorrhoea rates fall, and HIV rates falling in Australia as more join PrEP demo
World on track to reach the 90-90-90 targets for HIV treatment by 2020
WHO recommends package of tests, treatment and prevention for 'urgent need' people with HIV with low CD4 counts


Click here for more news reports and to learn more about NAM.

Partnership Information


IAS 2017 conference organizers are using social media to communicate with delegates attending the meeting and with those following the conference from home.

Social Media
IAS 2017 updates are available at Facebook, Twitter, YouTube, and Instagram.

For more information about these resources and IAS 2017, go to www.ias2017.org.

NAM is the official provider of online scientific news reporting for IAS 2017, via its Web site and summary emails bulletins during the week of the conference, and one in the week following the conference.

To view the coverage and to sign up for the bulletins (also available in French, Italian, Portuguese, Spanish, and Russian) go to www.aidsmap.com/ias2017.